logo
Start:
Jun 26, 2019, 9:00 AM
End:
Jun 26, 2019, 9:00 AM

Institutional Capital & Cannabis Conference Europe (IC3 Europe)

Location:

About Institutional Capital & Cannabis Conference Europe (IC3 Europe)

IMN is excited to announce a new partnership with Prohibition Partners, Europe’s leading provider of market and strategic insights into the European legal cannabis markets. IMN and Prohibition Partners will co-host the first annual Institutional Capital & Cannabis Conference Europe (IC3 Europe), June 26, in London.
With over double the population of the US and Canada combined, Europe is expected to become the largest legal cannabis market in the world, within the next five to ten years. Some analysts are estimating that the European legal cannabis market will be worth €125 billion by 2028. The multijurisdictional nature of Europe makes it a complex market but lessons can be learned from regulated markets as industry players look to take advantage of the opportunities that exist.
IMN’s IC3 forums are a meeting place for investors who wish to invest or learn more about this exciting and high-growth new asset class, cannabis companies and investment funds who are looking to raise money or showcase their products, and professional service providers who facilitate these groups doing business.
Our US conferences have earned a reputation for quality content, expert speakers, and a high representation of institutional investors. Previous IC3 participants include leading cannabis brands Canndescent, MedMen, MedReleaf, Flow Kana, Tikun Olam and funds such as Privateer Holdings (Tilray, Marley Natural), Casa Verde (Eaze), Gotham Green Partners (Cronos), Merida Capital (KushCo) and a number of ex-Wall Street professionals turned private investors.
IMN is excited to bring this one-of-kind forum aimed at sophisticated investors seeking alternative asset classes and portfolio diversification to the UK this June.

Speakers

Vivien Azer
Managing Director Cowen and Company
NARBE ALEXANDRIAN
President Canopy Rivers
Karan Wadhera
Managing Partner Casa Verde Capital
WILL MUECKE
Managing Member, Artemis Growth Partners
Anthony Dutton
CEO, Cannex Group
STEVE MALLOY
CEO, PharmaRolly Holdings BV
View More (13)
Alex Brooks
Senior Analyst Canaccord Genuity
BARINDER BHULLAR
VP Government Relations & International Affairs, Supreme Cannabis
Alfredo Pascual
International Analyst Marijuana Business Daily
MOLLY MEACHER
Chairman, APPG for Drug Policy Reform
HANNAH SIMON
Managing Director The Medical Cannabis Clinics
Tom Zuber
Managing Partner Zuber Lawler & Del Duca
JENNIFER SANDERS
Founder & CEO, CNS Equity Partners
CHI-CHIEN HOU
Managing Director at AFI Capital Partners
Nic Easley
CEO & Managing Director MULTIVERSE CAPITAL
Thomas Mazarakis
Portfolio Advisor Salveo Capital
Stephen Murphy
Co-Founder & Group Managing Director European Cannabis Holdings
Troy Dayton
CEO, The Arcview Group The ArcView Group
DRAKE SUTTON-SHEARER
CEO, PRØHBTD Media

Agenda

7:45 AM Breakfast & Registration
8:45 AM Global State of the Industry and Market Outlook
It’s 2019 and the global cannabis industry is undergoing a rapid evolution. Last year saw the legalisation of recreational cannabis use in Canada, significant progress made at the state level in the US, and the introduction of legislation in a number of European nations. This session will look at the numbers, highlighting the most promising growth markets in Europe and abroad.
9:15 AM Investment Opportunities in Legal Cannabis
10:00 AM Assessing the Upside of Investing in Europe
10:45 AM Networking Break
11:15 AM The Path to Public Markets
We take a look at the journeys of public companies in North America as they discuss their success stories, setbacks they overcame and pitfalls to be avoided.
12:00 PM Update on the Regulatory Landscape in Europe
Significant legislative events in Europe were witnessed by the sector last year. The UK legalized the limited prescribed use of medical cannabis products and Germany has issued more tenders for domestic medical cannabis production. Despite this, considerable issues with access remain.
This unique panel will examine the legislative and regulatory status of medical and recreational cannabis across Europe, how these laws and regulations are being implemented, and what the major stumbling blocks are when setting up such frameworks.
12:45 PM Lunch
1:45 PM Impact Investing: Medical Efficacy and Societal Impact of Legal Cannabis
More and more investors are looking to have an impact investing allocation in their portfolio. Social justice, regulatory reform and improving the overall health of our society make cannabis a prime fit for this allocation. This panel will address the socioeconomic benefits that a well-regulated cannabis industry can offer.
2:25 PM Strategic Approaches to Building a Successful Cannabis Business
There are many different approaches to building a business but in the growing cannabis space, there are certain things that every business and investor needs to know. This session will address the importance of intellectual property (IP) and protection strategies, along with scaling and the major differences between businesses “touching the plant” and “not touching the plant”.
3:05 PM Due Diligence Best Practice for Cannabis Investments
For many investors, this is their first time deploying capital into the space. As such their teams need to understand this unique investment opportunity. This panel of analysts and investors specialize in the cannabis sector and will discuss their processes and best practices.
3:45 PM Networking Break
4:00 PM From Theory to Reality: Invest Like the Best
4:40 PM Crystal Balling the Future of Cannabis in Europe
After a full, solid day of discussion, where does this leave us? What has surprised us in the past year and what can we expect for the months and years ahead? Industry leaders from business and policy discuss legalisation, regulation and what this means for all of you.
5:20 PM Keynote Session
5:40 PM Cocktail Reception
6:40 PM The Inaugural Institutional Capital & Cannabis Conference (Europe) Concludes